查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年富血小板血漿治療市場預測：按類型、來源、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383484

2030 年富血小板血漿治療市場預測：按類型、來源、應用、最終用戶和地區進行的全球分析

Platelet-rich Plasma Therapy Market Forecasts to 2030 - Global Analysis By Type, Source, Application, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球富血小板血漿治療（PRP）市場規模將達7.1094億美元，預測期內年複合成長率為14.97%，預計2030年將達到18.8765億美元。

一種稱為富血小板血漿療法 (PRP) 的尖端醫療技術利用人體的自​​然癒合能力來刺激組織再生。在治療過程中，抽取少量患者血液來濃縮血小板，血小板富含組織修復所需的生長因子和蛋白質。

根據美國紅十字會的數據，PRP 為每 50 mL 5.5 x 10 血小板或更多。這意味著與全血相比，血小板濃度增加了 2-7 倍。人體血小板濃度的正常範圍是每μL總靜脈血150,000至450,000個。

對非手術和微創治療的需求不斷增加

隨著越來越多的患者更喜歡停工時間較短、併發症風險較低的治療方法，對非手術和微創治療方法的需求正在增加。 PRP 療法順應了這一趨勢，為皮膚再生、肌腱損傷和慢性關節疼痛等疾病提供侵入性較小的治療方法。此外，利用身體自然癒合過程而不需要進行大量手術的概念對患者很有吸引力。

嚴格的保險保障

一個主要障礙是 PRP 治療的保險範圍有限。 PRP 治療通常是自費治療，這可能會阻礙一些對這種再生醫學感興趣的人。此外，缺乏廣泛的保險支持可能導致它們難以獲得和負擔得起，從而限制了它們的採用，特別是在保險依賴度較高的地區。

擴大臨床應用

一個有趣的前景是繼續研究 PRP 治療的新臨床應用。確定 PRP 在先前未研究的疾病中的可再生可能是未來研究的重點。此外，進一步研究PRP在神經病學、心血管醫學和自體免疫疾病等疾病中的功效可能會擴大PRP的潛在治療效用。

科學共識不足

由於缺乏公認的定義或一套 PRP 製備和給藥程序，損害了治療的合法性。此外，不同的治療參數和處理技術導致結果不一致，可能會使醫療保健提供者相互懷疑。為了應對這一威脅，必須透過研究和建立共識的努力建立統一的科學共識。

COVID-19 的影響：

富血小板血漿 (PRP) 治療市場受到了 COVID-19大流行的各種影響。一方面，PRP 療法的採用受到了由於衛生服務中斷、關閉和應對大流行的資源重新分配而導致選擇性和非緊急醫療程序暫時放緩的影響。然而，這場大流行凸顯了再生醫學的重要性，並更加重視以病人為中心的醫學和微創手術。隨著醫療保健系統的穩定，在新冠肺炎後的恢復期，對 PRP 治療的需求應該會增加，特別是對於肌肉骨骼疾病和美容應用。

富含白血球和富含血小板的血漿（L-PRP）部分預計在預測期內是最大的

富含白血球的富含血小板的血漿（L-PRP）部分佔最大佔有率。 L-PRP 的特徵是白血球濃度高，被認為參與組織再生和免疫反應。白血球的發炎特性可能有助於治療肌腱損傷和骨關節炎等疾病。此外，白血球被認為可以增強 PRP 的整體再生能力，使 L-PRP 在某些臨床情況下成為有利的選擇。 L-PRP 也用於口腔顎顏面外科。

預計美容醫學領域在預測期內的年複合成長率最高。

在富血小板血漿（PRP）市場中，美容醫療領域預計年複合成長率最高。 PRP 療法在美容醫學中的使用急劇增加，特別是在美容皮膚科和臉部回春。 PRP 由於其可促進膠原蛋白生成和組織修復的再生特性，作為皮膚再生、皺紋減少和頭髮修復的治療方法而受到關注。此外，PRP 治療是微創的，這符合非手術美容手術的日益普及。 PRP 在尋求持久自然美容解決方案的人們中越來越受歡迎，因為它以其均勻膚色、治療脫髮和改善整體臉部美觀的能力而聞名。Masu。

佔比最大的地區：

北美是富血小板血漿治療（PRP）市場佔有率最高的地區，也是該行業的主導地區。尤其美國，由於大量患者可以從再生治療中受益、研發方面的大量投資以及發達的醫療基礎設施等多種因素，對 PRP 市場的成長做出了重大貢獻。此外，PRP治療現已廣泛應用於許多醫學專業，包括整形外科、皮膚科和運動醫學。這部分歸因於該地區對醫療保健創新的關注和完善的法律規範。

複合年複合成長率最高的地區：

在富血小板血漿（PRP）市場成長方面，預計亞太地區的年複合成長率最高。隨著世界人口老化、尖端醫療意識增強以及對整形外科美容的擔憂增加，包括中國、日本、印度、印度等國家在內的亞太地區對再生醫學的需求正在迅速成長。韓國，正在做。此外，PRP 療法在肌肉骨骼疾病和運動醫學領域也越來越受歡迎。此外，該地區在全球 PRP 市場中的重要性與日俱增，這是政府支持醫療基礎設施發展的配合措施和對醫療旅遊業日益關注的結果。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球富血小板血漿治療 (PRP) 市場：按類型

  • 純富血小板血漿 (P-PRP)
  • 富含白血球的富含血小板的血漿（L-PRP）
  • 純血小板富含纖維蛋白 (P-PRF)
  • 富含白血球和富含血小板的纖維蛋白 (L-PRF)
  • 啟動PRP
  • 自動調節血漿 (ACP)
  • 細胞PRP
  • 其他類型

第6章 全球富血小板血漿治療 (PRP) 市場：依來源分類

  • 自體的
  • 同種異體的
  • 其他來源

第7章 全球富血小板血漿治療 (PRP) 市場：依應用分類

  • 整形外科
  • 皮膚科
  • 牙科
  • 運動醫學
  • 慢性傷口
  • 眼科
  • 美容醫學
  • 心肌損傷
  • 其他用途

第8章 全球富血小板血漿治療 (PRP) 市場：按最終用戶分類

  • 醫院
  • 診所
  • 研究和學術機構
  • 其他最終用戶

第9章 全球富血小板血漿治療（PRP）市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Arthrex, Inc
  • Zimmer Biomet
  • EmCyte Corporation
  • Dr. PRP USA LLC
  • Juventix Regenerative Medical LLC
  • Johnson & Johnson Services, Inc.
  • Terumo Corporation
  • Stryker
  • Apex Biologix
  • Celling Biosciences, Inc
Product Code: SMRC24332

According to Stratistics MRC, the Global Platelet-rich Plasma Therapy (PRP) Market is accounted for $710.94 million in 2023 and is expected to reach $1887.65 million by 2030 growing at a CAGR of 14.97% during the forecast period. A state-of-the-art medical technique called platelet-rich plasma therapy (PRP) uses the body's own natural healing abilities to encourage tissue regeneration. In order to concentrate the platelets-which are abundant in growth factors and proteins necessary for tissue repair-a small amount of the patient's blood is extracted during the course of the treatment.

According to the American Red Cross, PRP is greater than or equal to 5.5 × 1010 platelets per 50 mL. This translates to a two- to sevenfold increase in platelet concentration compared with that of whole blood. The normal human range of platelet concentration is 150 000 to 450 000 platelets per µL of whole venous blood.

Market Dynamics:

Driver:

Growing need for non-surgical and low-invasive therapies

Patients' increasing preference for procedures with less downtime and a lower risk of complications is driving the demand for non-surgical and minimally invasive treatments. PRP therapy is in line with this trend by providing a less invasive treatment for ailments like skin rejuvenation, tendon injuries, and chronic joint pain. Additionally, the concept of utilizing the body's natural healing processes instead of requiring extensive surgery appeals to patients.

Restraint:

Strict insurance protection

The limited insurance provider coverage of PRP therapy is a major impediment. PRP treatment is frequently paid for by the patient, which may be a deterrent for some people interested in this regenerative medicine. Moreover, a lack of broad insurance support could make it more difficult to use and less affordable, which would restrict its adoption, especially in areas where people rely more heavily on insurance.

Opportunity:

Increasing the use of clinical applications

An interesting prospect is the continuous investigation of novel clinical uses for PRP therapy. Determining PRP's regenerative potential in diseases that haven't been studied before can be the focus of future research. Additionally, PRP's potential therapeutic utility may be expanded by further investigating its effectiveness in neurology, cardiovascular medicine, and autoimmune disorders, among other diseases.

Threat:

Insufficient scientific consensus

The legitimacy of the therapy is at risk since there is no accepted definition or set of procedures for the preparation and administration of PRP. Moreover, healthcare providers may become skeptical of one another if treatment parameters and processing techniques vary and produce inconsistent results. To counter this threat, a unified scientific consensus must be established through research and consensus-building efforts.

COVID-19 Impact:

The market for platelet-rich plasma (PRP) therapy has been impacted by the COVID-19 pandemic in a number of ways. On the one hand, the adoption of PRP therapy has been impacted by the temporary slowdown in elective and non-urgent medical procedures brought on by disruptions in healthcare services, lockdowns, and resource reallocation towards pandemic response. However, the pandemic has highlighted the significance of regenerative medicine, placing a greater focus on patient-centered care and minimally invasive procedures. As healthcare systems stabilize, there should be a rise in demand for PRP therapy in the post-COVID recovery period, particularly in musculoskeletal conditions and aesthetic applications.

The Leukocyte-rich Platelet-rich Plasma (L-PRP) segment is expected to be the largest during the forecast period

The segment leukocyte-rich platelet-rich plasma (L-PRP) holds the largest share. A higher concentration of white blood cells, which are thought to be involved in tissue regeneration and the immune response, is a characteristic of L-PRP. This particular segment is preferred in some medical applications, especially in orthopedics, where the anti-inflammatory characteristics of leukocytes may help treat ailments like tendon injuries and osteoarthritis. Moreover, leukocytes are assumed to augment PRP's overall regenerative capacity, rendering L-PRP favored option in particular clinical situations. L-PRP has also been used in oral and maxillofacial surgery.

The Aesthetic Medicine segment is expected to have the highest CAGR during the forecast period

In the platelet-rich plasma (PRP) market, the aesthetic medicine segment is projected to have the highest CAGR. PRP therapy use in aesthetic medicine has increased dramatically, especially in cosmetic dermatology and facial rejuvenation. PRP is a sought-after treatment for skin rejuvenation, wrinkle reduction, and hair restoration because of its regenerative qualities, which encourage collagen production and tissue repair. Additionally, PRP treatments are minimally invasive, which is in line with the rising popularity of non-surgical aesthetic procedures. PRP is becoming more and more popular among people looking for long-lasting, natural cosmetic solutions as a result of growing knowledge of its efficacy in improving skin texture, treating hair loss, and improving overall facial aesthetics.

Region with largest share:

With the largest market share for platelet-rich plasma (PRP), North America has been a dominant region in the industry. Due to a number of factors, including a highly prevalent patient population that can benefit from regenerative therapies, substantial investment in research and development, and an advanced healthcare infrastructure, the United States in particular has contributed significantly to the growth of the PRP market. Furthermore, PRP treatments are now widely used in many medical specialties, including orthopedics, dermatology, and sports medicine. This is due in part to the region's strong focus on technological innovation in healthcare and its well-established regulatory framework.

Region with highest CAGR:

In terms of platelet-rich plasma (PRP) market growth, the Asia-Pacific region is projected to have the highest CAGR. As the world's population ages and becomes more aware of cutting-edge medical treatments, as well as the increasing prevalence of orthopedic and cosmetic concerns, the Asia-Pacific region-which includes countries like China, Japan, India, and South Korea-is seeing a sharp increase in demand for regenerative medicine. Plus, PRP therapy is becoming more and more popular in the areas of musculoskeletal disorders and sports medicine. Moreover, the area's growing importance in the global PRP market is a result of government initiatives supporting the development of healthcare infrastructure as well as a growing focus on medical tourism.

Key players in the market

Some of the key players in Platelet-rich Plasma Therapy (PRP) market include: Arthrex, Inc, Zimmer Biomet, EmCyte Corporation, Dr. PRP USA LLC, Juventix Regenerative Medical LLC, Johnson & Johnson Services, Inc., Terumo Corporation, Stryker, Apex Biologix and Celling Biosciences, Inc.

Key Developments:

In June 2023, Dr. PRP USA LLC is proud to announce it has received 510K approval from the Food & Drug Administration (FDA) for its PRP kits. Now that the 510K clearance is final, Dr. PRP can continue to expand its market providing PRP kits to medical providers.

In May 2023, Zimmer Biomet Holdings, Inc., a global medical technology leader, announced it has reached a definitive agreement to acquire OSSIS, a privately-held medical device company that specializes in personalized 3D printed implants, as well as complex hip replacements, including second-time hip replacements and replacements involving bone tumors and trauma.

In January 2023, Arthrex, a global leader in minimally invasive surgical technology, announced its ACL TightRope implant has received clearance from the U.S. Food and Drug Administration (FDA) for pediatric indications. The TightRope implant is used in the surgical treatment of orthopedic injuries and is the first and only fixation device for anterior cruciate ligament (ACL) injuries cleared for pediatric use.

Types Covered:

  • Pure-Platelet-rich Plasma (P-PRP)
  • Leukocyte-rich Platelet-rich Plasma (L-PRP)
  • Pure-Platelet-rich Fibrin (P-PRF)
  • Leukocyte-rich Platelet-rich Fibrin (L-PRF)
  • Activated PRP
  • Autologous Conditioned Plasma (ACP)
  • Cellular PRP
  • Other Types

Sources Covered:

  • Autologous
  • Allogenic
  • Other Sources

Applications Covered:

  • Orthopedics
  • Dermatology
  • Dental
  • Sports Medicine
  • Chronic Wounds
  • Ophthalmology
  • Aesthetic Medicine
  • Cardiac Muscle Injury
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Research and Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

,

5 Global Platelet-rich Plasma Therapy (prp) Market, By Type

  • 5.1 Introduction
  • 5.2 Pure-Platelet-rich Plasma (P-PRP)
  • 5.3 Leukocyte-rich Platelet-rich Plasma (L-PRP)
  • 5.4 Pure-Platelet-rich Fibrin (P-PRF)
  • 5.5 Leukocyte-rich Platelet-rich Fibrin (L-PRF)
  • 5.6 Activated PRP
  • 5.7 Autologous Conditioned Plasma (ACP)
  • 5.8 Cellular PRP
  • 5.9 Other Types

6 Global Platelet-rich Plasma Therapy (prp) Market, By Source

  • 6.1 Introduction
  • 6.2 Autologous
  • 6.3 Allogenic
  • 6.4 Other Sources

7 Global Platelet-rich Plasma Therapy (prp) Market, By Application

  • 7.1 Introduction
  • 7.2 Orthopedics
  • 7.3 Dermatology
  • 7.4 Dental
  • 7.5 Sports Medicine
  • 7.6 Chronic Wounds
  • 7.7 Ophthalmology
  • 7.8 Aesthetic Medicine
  • 7.9 Cardiac Muscle Injury
  • 7.10 Other Applications

8 Global Platelet-rich Plasma Therapy (prp) Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Research and Academic Institutes
  • 8.5 Other End Users

9 Global Platelet-rich Plasma Therapy (prp) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Arthrex, Inc
  • 11.2 Zimmer Biomet
  • 11.3 EmCyte Corporation
  • 11.4 Dr. PRP USA LLC
  • 11.5 Juventix Regenerative Medical LLC
  • 11.6 Johnson & Johnson Services, Inc.
  • 11.7 Terumo Corporation
  • 11.8 Stryker
  • 11.9 Apex Biologix
  • 11.10 Celling Biosciences, Inc

List of Tables

  • Table 1 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Pure-Platelet-rich Plasma (P-PRP) (2021-2030) ($MN)
  • Table 4 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Leukocyte-rich Platelet-rich Plasma (L-PRP) (2021-2030) ($MN)
  • Table 5 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Pure-Platelet-rich Fibrin (P-PRF) (2021-2030) ($MN)
  • Table 6 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Leukocyte-rich Platelet-rich Fibrin (L-PRF) (2021-2030) ($MN)
  • Table 7 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Activated PRP (2021-2030) ($MN)
  • Table 8 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Autologous Conditioned Plasma (ACP) (2021-2030) ($MN)
  • Table 9 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Cellular PRP (2021-2030) ($MN)
  • Table 10 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Source (2021-2030) ($MN)
  • Table 12 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Autologous (2021-2030) ($MN)
  • Table 13 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Allogenic (2021-2030) ($MN)
  • Table 14 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 15 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Application (2021-2030) ($MN)
  • Table 16 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Orthopedics (2021-2030) ($MN)
  • Table 17 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 18 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Dental (2021-2030) ($MN)
  • Table 19 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Sports Medicine (2021-2030) ($MN)
  • Table 20 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Chronic Wounds (2021-2030) ($MN)
  • Table 21 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Ophthalmology (2021-2030) ($MN)
  • Table 22 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Aesthetic Medicine (2021-2030) ($MN)
  • Table 23 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Cardiac Muscle Injury (2021-2030) ($MN)
  • Table 24 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 28 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Research and Academic Institutes (2021-2030) ($MN)
  • Table 29 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.